Lenvatinib plus pembrolizumab (L plus P) vs sunitinib (S) in advanced renal cell carcinoma (aRCC): Patterns of progression and subsequent therapy in the CLEAR trial

被引：0
|
作者：
Grunwald, Viktor
Motzer, Robert J.
Keizman, Daniel
Bedke, Jens
Schmidinger, Manuela
Staehler, Michael D.
Matveev, Vsevolod B.
George, Saby
Hutson, Thomas E.
Vaishampayan, Ulka N.
Merchan, Jaime R.
Eto, Masatoshi
Rha, Sun Young
Waddell, Tom
Sabbatini, Roberto
Barthelemy, Philippe
Burgents, Joseph E.
Ren, Min
Brown, Ian
Choueiri, Toni K.
机构：
[1] Univ Hosp Essen, Essen, Germany
[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[3] Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel
[4] Klinikum Stuttgart, Dept Urol, Stuttgart, Germany
[5] Klinikum Stuttgart, Eva Mayr Stihl Canc Ctr, Stuttgart, Germany
[6] Med Univ Vienna, Vienna, Austria
[7] Univ Hosp Munich, Munich, Germany
[8] Minist Hlth Russian Federat, State Budgetary Inst NN Blokhin Natl Med Res Ctr, Moscow, Russia
[9] Roswell Park Canc Inst, Buffalo, NY 14263 USA
[10] Texas Oncol, Dallas, TX USA
[11] Univ Michigan, Rogel Canc Ctr, Ann Arbor, MI 48109 USA
[12] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA
[13] Kyushu Univ, Fukuoka, Japan
[14] Yonsei Univ Hlth Syst, Yonsei Canc Ctr, Seoul, South Korea
[15] Christie NHS Fdn Trust, Manchester, Lancs, England
[16] Univ Hosp Modena, Modena, Italy
[17] Strasbourg European Canc Inst, Strasbourg, France
[18] Merck & Co Inc, Rahway, NJ 07065 USA
[19] Eisai Inc, Nutley, NJ USA
[20] Eisai Ltd, Hatfield, Herts, England
[21] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4524
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Impact of subsequent therapies in patients (pts) with advanced renal cell carcinoma (aRCC) receiving lenvatinib plus pembrolizumab (LEN plus PEMBRO) or sunitinib (SUN) in the CLEAR study.
    Voss, Martin H.
    Powles, Thomas
    McGregor, Bradley Alexander
    Porta, Camillo
    Gruenwald, Viktor
    Merchan, Jaime R.
    Rolland, Frederic
    Maroto-Rey, Pablo
    Goh, Jeffrey C.
    Xing, Dongyuan
    Perini, Rodolfo F.
    McKenzie, Jodi
    Mody, Kalgi
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [2] Updated efficacy of lenvatinib (LEN) plus pembrolizumab (PEMBRO) vs sunitinib (SUN) in patients (pts) with advanced renal cell carcinoma (aRCC) in the CLEAR study
    Porta, C. G.
    Eto, M.
    Motzer, R. J.
    De Giorgi, U. F. F.
    Buchler, T.
    Basappa, N. S.
    Mendez Vidal, M. J.
    Tjulandin, S.
    Park, S. H.
    Melichar, B.
    Hutson, T. E.
    Alemany, C.
    McGregor, B.
    He, C. S.
    Perini, R.
    Mody, K.
    McKenzie, J.
    Choueiri, T. K.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1205 - +
  • [3] Final prespecified overall survival (OS) analysis of the phase 3 CLEAR trial: 4-year follow-up of lenvatinib plus pembrolizumab (L plus P) vs sunitinib (S) in patients with advanced renal cell carcinoma (aRCC)
    Motzer, Robert J.
    Porta, Camillo
    Eto, Masatoshi
    Powles, Thomas
    Grunwald, Viktor
    Hutson, Thomas E.
    Alekseev, Boris
    Rha, Sun Young
    Merchan, Jamie R.
    Goh, Jeffrey C.
    De Giorgi, Ugo
    Melichar, Bohuslav
    Hong, Sung-Hoo
    Gurney, Howard
    Rodriguez-Lopez, Karla
    He, Cixin S.
    Okpara, Chinyere E.
    McKenzie, Jodi
    Choueiri, Toni K.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2023, 19 : 72 - 73
  • [4] Final prespecified overall survival (OS) analysis of CLEAR: 4-year follow-up of lenvatinib plus pembrolizumab (L plus P) vs sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC)
    Motzer, Robert J.
    Porta, Camillo
    Eto, Masatoshi
    Powles, Thomas
    Gruenwald, Viktor
    Hutson, Thomas E.
    Alekseev, Boris
    Rha, Sun Young
    Merchan, Jaime R.
    Goh, Jeffrey C.
    Kapoor, Anil
    De Giorgi, Ugo
    Melichar, Bohuslav
    Hong, Sung-Hoo
    Gurney, Howard
    Rodriguez-Lopez, Karla
    He, Cixin S.
    Okpara, Chinyere
    McKenzie, Jodi
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [5] Updated efficacy of lenvatinib (LEN) plus pembrolizumab (PEMBRO) versus sunitinib (SUN) in patients with advanced renal cell carcinoma (aRCC) in the CLEAR study
    Porta, Camillo G.
    Eto, Masatoshi
    Motzer, Robert J.
    De Giorgi, Ugo
    Buchler, Tomas
    Basappa, Naveen S.
    Mendez Vidal, Maria Jose
    Tjulandin, Sergei
    Park, Se Hoon
    Melichar, Bohuslav
    Hutson, Thomas
    Alemany, Carlos
    McGregor, Bradley
    He, Cixin Steven
    Perini, Rodolfo
    Mody, Kalgi
    McKenzie, Jodi
    Ebaid, Basant
    Choueiri, Toni
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 122 - 123
  • [6] Efficacy and safety of lenvatinib plus pembrolizumab vs sunitinib in the East Asian subset of patients with advanced renal cell carcinoma from the CLEAR trial
    Rha, Sun Young
    Choueiri, Toni K.
    Matveev, Vsevolod B.
    Alyasova, Anna
    Hong, Sung-Hoo
    Gordoa, Teresa Alonso
    Gurney, Howard
    Bjarnason, Georg A.
    Buchler, Tomas
    Pedrazzoli, Paolo
    Takagi, Toshio
    Park, Se Hoon
    Lee, Jae Lyun
    Perini, Rodolfo F.
    He, Cixin S. S.
    McKenzie, Jodi A.
    Eto, Masatoshi
    INTERNATIONAL JOURNAL OF CANCER, 2023, 153 (06) : 1241 - 1250
  • [7] Lenvatinib plus pembrolizumab versus sunitinib for advanced renal cell carcinoma: Japanese patients from the CLEAR study
    Eto, Masatoshi
    Takagi, Toshio
    Kimura, Go
    Fukasawa, Satoshi
    Tamada, Satoshi
    Miura, Yuji
    Oya, Mototsugu
    Sassa, Naoto
    Anai, Satoshi
    Nozawa, Masahiro
    Sakai, Hideki
    Perini, Rodolfo
    Yusa, Wataru
    Ikezawa, Hiroki
    Narita, Tomoyuki
    Tomita, Yoshihiko
    CANCER MEDICINE, 2023, 12 (06): : 6902 - 6912
  • [8] Analyses on impact of tumor burden at progression and changes in IMDC from baseline in patients (pts) with advanced renal cell carcinoma (aRCC) treated with lenvatinib plus pembrolizumab (L plus P) in the phase 3 CLEAR trial.
    Keizman, Daniel
    Bedke, Jens
    Staehler, Michael D.
    Matveev, Vsevolod B.
    George, Saby
    Hutson, Thomas E.
    Vaishampayan, Ulka N.
    Merchan, Jaime R.
    Eto, Masatoshi
    Rha, Sun Young
    Waddell, Tom
    Sabbatini, Roberto
    Barthelemy, Philippe
    Burgents, Joseph E.
    Ren, Min
    Brown, Ian
    Saal, Hakim
    Choueiri, Toni K.
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL) : 531 - 531
  • [9] Tumor response by baseline metastases in patients (pts) with renal cell carcinoma (RCC) treated with lenvatinib (L) plus pembrolizumab (P) vs sunitinib (S): Post hoc analysis of the CLEAR trial
    Gruenwald, V.
    Mckay, R. R.
    Buchler, T.
    Eto, M.
    Park, S. H.
    Takagi, T.
    Zanetta, S.
    Keizman, D.
    Suarez Rodriguez, C.
    Negrier, S.
    Lee, J-L.
    Santini, D.
    Bedke, J.
    Staehler, M.
    Kollmannsberger, C. K.
    Choueiri, T. K.
    Motzer, R. J.
    Burgents, J.
    Okpara, C. E.
    Powles, T. B.
    ANNALS OF ONCOLOGY, 2023, 34 : S1024 - S1025
  • [10] Characterization and management of adverse reactions (ARs) in patients with advanced renal cell carcinoma (aRCC) receiving lenvatinib plus pembrolizumab (CLEAR study)
    Motzer, Robert
    George, Saby
    Merchan, Jaime R.
    Hutson, Thomas E.
    Song, Xun
    Perini, Rodolfo F.
    Xie, Ran
    Bapat, Urmi
    Ebaid, Basant
    Puente, Javier
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 121 - 122
12345